Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BOMPA: Bosentan for Mild Pulmonary Vascular Disease in ASD Patients
NCT01218607Phase 3Completed
- Sponsor
- UZ Leuven
- Start
- Oct 2010
- Primary completion
- Mar 2014
- Modality
- Nucleic Acid-Directed Small Molecules, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in pulmonary vascular disease (PVD) comparing Bosentan with Placebo (2 arms). Primary endpoint: Pulmonary vascular resistance at 16 weeks. Started Oct 2010; status: completed.
02
Drugs
bosentan
03
Conditions
pulmonary vascular disease (PVD)
Beyond the preview
Go deeper on NCT01218607.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01218607.